Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.

Qin, Shukui; Bi, Feng; Jin, Jie; Cheng, Ying; Guo, Jun; Ren, Xiubao; Huang, Yiran; Tarazi, Jamal; Tang, Jie; Chen, Connie; Kim, Sinil; Ye, Dingwei

Qin, Shukui; Bi, Feng; Jin, Jie; Cheng, Ying; Guo, Jun; Ren, Xiubao; Huang, Yiran; Tarazi, Jamal; Tang, Jie; Chen, Connie; Kim, Sinil; Ye, Dingwei.

Qin S; Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, People's Republic of China.
Bi F; Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Jin J; Department of Urology, Peking University First Hospital, Beijing, People's Republic of China.
Cheng Y; Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, Jilin Province, People's Republic of China.
Guo J; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital/Institute, Beijing, People's Republic of China.
Ren X; Department of Biology Treatment, Tianjin Oncology Hospital, Tianjin, People's Republic of China.
Huang Y; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Tarazi J; Clinical Development, Pfizer Oncology, San Diego, CA, USA.
Tang J; Global Outcomes Research, Pfizer Inc., New York, NY, USA.
Chen C; Global Outcomes Research, Pfizer Inc., New York, NY, USA.
Kim S; Clinical Development, Pfizer Oncology, San Diego, CA, USA.
Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.